

UCSF

UC San Francisco Previously Published Works

Title

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group

Permalink

<https://escholarship.org/uc/item/84b9n520>

Journal

British Journal of Cancer, 120(8)

ISSN

0007-0920

Authors

Shulman, David S
Klega, Kelly
Imamovic-Tuco, Alma
[et al.](#)

Publication Date

2019-04-16

DOI

10.1038/s41416-019-0424-7

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



CORRECTION

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group

David S. Shulman¹, Kelly Klega¹, Alma Imamovic-Tuco¹, Andrea Clapp², Anwasha Nag², Aaron R. Thorner², Eliezer Van Allen^{3,4}, Gavin Ha⁴, Stephen L. Lessnick⁵, Richard Gorlick⁶, Katherine A. Janeway¹, Patrick J. Leavey⁷, Leo Mascarenhas⁸, Wendy B. London¹, Kieuhoa T. Vo⁹, Kimberly Stegmaier¹, David Hall¹⁰, Mark D. Krailo^{10,11}, Donald A. Barkauskas^{10,11}, Steven G. DuBois¹ and Brian D. Crompton^{1,4,12}

British Journal of Cancer (2019) 120:869; <https://doi.org/10.1038/s41416-019-0424-7>

Correction to: *British Journal of Cancer* (2018) **119**, 615-621; <https://doi.org/10.1038/s41416-018-0212-9>; www.bjcancer.com; published online 21 August 2018

The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced.

In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain ($n = 30$) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain ($n = 11$) in ctDNA ($p = 0.18$; Fig. 3).

¹Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA; ²Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA; ³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁴Broad Institute, Cambridge, MA, USA; ⁵Center for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital Research Institute and the Division of Pediatric Heme/Onc/BMT at The Ohio State University, Columbus, OH, USA; ⁶Department of Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ⁷Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; ⁸Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁹Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco School of Medicine, San Francisco, CA, USA; ¹⁰Children's Oncology Group, Monrovia, CA, USA and ¹¹Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Correspondence: Brian D. Crompton (briand_crompton@dfci.harvard.edu)

¹²Present address: Department of Pediatric Oncology, 450 Brookline Avenue, Boston, MA, USA

These authors contributed equally: Steven G. DuBois, Brian D. Crompton.

Published online: 18 March 2019